Doccla, a leading provider of virtual ward and remote patient monitoring services, has raised £35 million in a Series B funding round. This significant investment, led by Lakestar with participation from new investor Elaia and existing backers General Catalyst, Bertelsmann Investments, and Speedinvest, marks a crucial step in Doccla's mission to revolutionize healthcare delivery. The funds will be used to consolidate Doccla’s market-leading position in the UK and Ireland and fuel its expansion across Europe, particularly in France and the DACH region.

Innovating Healthcare with Virtual Wards

Doccla was established to bridge a critical gap in healthcare by offering hospital-level care and monitoring in the comfort of patients' homes. The company's technology enables early discharge for patients who no longer require inpatient care while ensuring that chronic care patients can avoid unnecessary hospital admissions. This approach not only alleviates the pressure on healthcare systems but also enhances the patient experience by allowing them to recover in familiar surroundings.

At the core of Doccla’s service is a suite of monitoring devices provided to patients, which collect real-time data that is integrated into electronic health records. Healthcare professionals can access this data through a clinician dashboard, allowing them to monitor patient health remotely and respond to potential issues before they become critical. This proactive approach has been particularly successful in the UK, where Doccla works with NHS Trusts across more than half of the NHS regions, and in Ireland, where it recently partnered with the Health Service Executive (HSE).

Expanding Across Europe

The new funding will enable Doccla to scale its operations across Europe, with a focus on France and the DACH region (Germany, Austria, and Switzerland). Doccla’s expansion strategy is methodical, typically involving the establishment of partnerships with local healthcare providers before entering new markets. This approach has already been successful in Germany, and Doccla aims to replicate this model in other European countries.

Beyond its core focus on virtual ward services, Doccla is also exploring opportunities in the life sciences sector, particularly in supporting virtual clinical trials for pharmaceutical companies. By reducing the need for patients to visit physical clinics during drug trials, Doccla's technology offers a more efficient and cost-effective alternative to traditional research methods.

A Vision for the Future

Doccla’s rapid growth and success have positioned it as a market leader in the UK, and the company is now poised to expand its influence across Europe. With Lakestar partner Oliver Heimes joining Doccla’s board, there is strong confidence in the company's ability to maintain its leadership position, diversify its services, and successfully enter new markets.

The £35 million Series B funding round is a pivotal moment for Doccla as it continues to innovate in the healthcare sector. With plans to expand across Europe and explore new opportunities in the life sciences, Doccla is well-positioned to lead the way in virtual ward services. As healthcare systems around the world look for innovative solutions to improve patient care and manage resources more effectively, Doccla’s technology-enabled approach offers a promising future.